Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
PR Newswire•05/08/2026•16:05 ET
0
Whiz Insights
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile
Get started
Create a free account to read the full story.